Skip to main content
. 2019 Mar 30;8(6):e1586042. doi: 10.1080/2162402X.2019.1586042

Figure 5.

Figure 5.

T cell response to neoantigens in vivo. a) Flow plot of CD137+/CD8+ T cells (top) and IFNγ+/CD8 + T cells (bottom) after coculturing patient’s T cells with tumor lysate from P0 (right side), no lysate (left side) or P0 tumor lysate incubated with HLA-A2+ healthy donor’s PBMCs (Negative control). b) Barplot showing the percentage of CD137+/CD8+ T cells (left) and IFN©+/CD8 + T cells (right) stimulated by tumor lysate (*, p < 0.05; **, p < 0.01, ANOVA with Tukey post-hoc correction). c) Flow plot showing CD3 + T cells in the blood two weeks after ACT with peptide naïve T cells (ACT NP) or T cells stimulated with a cocktail of mutated peptides (ACT Mut). d) Quantification of the CD3 + T cells in the blood two weeks post ACT. *, p < 0.05 (Student’s t-test). e) Growth curve of subcutaneous tumors in mice that received ACT using T cells primed with neoantigens (red line, ACT NP) or no peptide (black line, ACT Mut). (*, p < 0.05; ANOVA with Tukey post-hoc correction).